Enorama Pharma

Enorama Pharma AB (publ), reg. no. 556716-5591 (the "Company" or "Enorama Pharma") has on 13 February 2026 resolved to prepare a balance sheet for liquidation purposes in accordance with Chapter 25, Section 13 of the Companies Act (2005:551) (Sw. aktiebolagslagen) because the board of directors found reason to assume that the equity was less than half of the registered share capital.

Due to the above, the board of directors of Enorama Pharma has prepared a balance sheet for liquidation purposes which has been reviewed by the Company's auditor. The balance sheet for liquidation purposes shows that the Company's equity amounts to SEK -25,559,465, which means that the equity is less than half of the registered share capital of approximately SEK 11,654,481. The board of directors has therefore decided to convene an extraordinary general meeting as soon as possible to determine whether to continue the Company's operations (so-called first control meeting according to the Companies Act). The notice will be published shortly.

The main reason for the negative equity is that the Company's subsidiary Enorama Pharma Inc. has received a Refuse-to-File decision from the U.S. Food and Drug Administration regarding the subsidiary's applications for prior approval of tobacco products, which meant that the assets related to the Company's subsidiary needed to be revalued. Enorama Pharma published information about the Refuse-to-File decision on 2 February 2026.

CONTACT

Enorama Pharma AB (publ)

Bengt Jönsson, CEO

info@enorama.se

Strandvägen 7A, 114 51 Stockholm

www.enorama.se

Enorama Pharma AB (publ) is listed on Nasdaq First North Growth Market.

The Company's Certified Adviser is Tapper Partners AB, +46 (0)70 44 010 98, ca@tapperpartners.se.

ABOUT ENORAMA PHARMA

Enorama Pharma's vision is to be a leading global manufacturer and supplier of consumer-friendly, oral nicotine products. The Company intends to expand through product and brand development and by establishing strategically important partnerships. For more information, visit www.enorama.se.

This disclosure contains information that Enorama Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU No 596/2014). The information was submitted for publication, through the agency of the contact person, on 11 March 2026 at 15.00 CET.